3Mosselman S, Polman J, Dijkema R. ER-β: identification and characterization of a novel human estrogen receptor[J]. FEBS Lett,1996,392( 1 ) :49 - 53.
4Cullen R, Maguire TM, McDermott EW, et al. Studies on oestrogen receptor-alpha and-beta mRNA in breast cancer[J]. Ettr J Cancer,2001,37(9) : 1118 - 1122.
5Pace P,Taylor J,Suntharalingam S, et al. Human estrogen receptor-β binds DNA in a manner similar to and dimerizes with estrogen receptor α [J] .J Biol Chem, 1997,272(41 ) :25832 - 25838.
6Wood JR, Likhite VS, Loven MA, et al. Allosteric modulation of estrogen receptor conformation by different estrogen response elements[J]. Mol Endocrinol, 2001,15(7) : 1114 - 1126.
7Kodama M, Kodama T. A new trend of breast cancer research in the genome era[J]. Int J Mol Med,2001,8(3) :291 -302.
8Mclnemey EM, Katzenellenbogen Bs. Different regions in activation functional of the human estrogen receptor required for antiestrogen and estradiol-dependent transcription activation [ J ]. J Biol Chem,1996,271 (39) :24172 - 24178.
9Webb P, Lopez GN, Uht RM, et cd. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens[ J ]. Mol Endocrinol, 1995,9(4) :443 - 456.
10Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor [J]. Nature, 1997, 389(6652) :753 - 758.
1Eiermann W, Pienkowski T, Crown J, et al.Phase 111 study ofdoxorubicin/cyclophosphamide with concomitant versus sequentialdocetaxel as adjuvant treatment in patients with human epidermalgrowth factor receptor 2 -normal, node -positive breast cancer:BCIRG-005 trial[j]. J Clin Oncol, 2011,29(29):3877-3884.
2Sugarman S, Wasserheit C, Hodgman E, et al. A pilot study ofdose -dense adjuvant paclitaxel without growth factor support forwomen with early breast carcinoma [J]. Breast Cancer Res Treat,2009 ,115(3):609-612.
3Murthy R,Gupta A,Hegde S, et al. Bilateral multiple extraocularmuscle metastasis from breast carcinoma [J]. Indian J Ophthalmol,2011,59(5): 381-382.
